Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8240115 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 5 Pages |
Abstract
The severe pulmonary toxicity observed in this study has been attributed to an interaction between gemcitabine and bleomycin. Gemcitabine (when administered without bleomycin) remains of interest in Hodgkin's lymphoma and is being incorporated into a new German Hodgkin's Lymphoma Study Group protocol that also includes consolidative radiotherapy. This study supports the concept of the integration of radiotherapy in gemcitabine-containing regimens in Hodgkin's lymphoma if there is an interval of at least 4 weeks between the two modalities and with a schedule whereby radiotherapy follows the chemotherapy.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Andrew F.R.A.N.Z.C.R., Henning M.D., Rolf-Peter M.D., Volker M.D., Andreas M.D., Hans Theodor M.D.,